Skip to main content
16/05/2024

Vall d'Hebron boosts the search for new drugs for head and neck cancer

Grup de Recerca Biomèdica en Cèl·lules Mare del Càncer del VHIR

VHIR team leading the studies.

Descobriment de fàrmacs per al càncer de cap i coll

Procés del descobriment de fàrmacs per al càncer de cap i coll.

16/05/2024

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

Head and neck cancer is a poorly studied disease, with a high rate of relapse and mortality. The Biomedical Research in Cancer Stem Cells group at Vall d'Hebron Research Institute (VHIR) has identified a new therapeutic target involved in the acquisition of resistance to chemotherapy in patients with head and neck squamous cell carcinomas (HNSCC). Finding new therapies for this type of tumor is the main objective of this group.

In work carried out to date, the VHIR team has discovered a new therapeutic target against head and neck cancer. It is a cell membrane receptor that is a key factor in the acquisition of resistance to the usual treatment in HNSCC.

With the aim of obtaining new therapies for patients, especially for those who are resistant to conventional chemotherapy, virtual screening has been carried out using artificial intelligence tools and several compounds with antitumor activity have been identified and tested in cells in culture and in animal models*.

"When investigating new drugs against this target, we have found very promising results, but we have seen that these drugs do not spread well in the organism", assures Dr. Matilde E. LLeonart, head of the Biomedical Research in Cancer Stem Cells group at VHIR. "We are currently refining these compounds to improve their therapeutic efficacy", adds Dr. LLeonart. This process includes chemical modifications to ensure that the drugs are effective and safe for clinical application.

So far, results show that these drugs would help overcome treatment-associated resistance. "We hope that our research will open the door to a change in clinical practice, with new therapeutic options to increase the survival of patients with HNSCC and even with other types of resistant tumors", concludes Dr. LLeonart.

The project has recently received a grant from the Generalitat de Catalunya (Convocatoria LLavors, AGAUR) for its great potential for transferability to the clinic. To encourage the implementation of new treatments for this type of tumors, the team has recently set up a crowdfunding campaign.

 

*Institutional Declaration on the Use of Animals in Research

 

Related news

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

Related professionals

Ana María García Arumí

Ana María García Arumí

Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Rebeca Murillo Torres

Rebeca Murillo Torres

Research technician
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Joan Piñas Massó

Joan Piñas Massó

Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Marina Bataller Fernández

Marina Bataller Fernández

Predoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.